Kodiak Sciences Inc (OQ:KOD)

Mar 28, 2024 06:30 am ET
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points  New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting  Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024  New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab investigational groups versus aflibercept targeted to start recruitment mid-2024 following completion of FDA discussions  Investor day to be scheduled after on-going regula
Mar 26, 2024 06:15 am ET
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024.
Jan 30, 2024 05:30 am ET
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
Jan 04, 2024 03:15 pm ET
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Nov 21, 2023 03:15 pm ET
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
PALO ALTO, Calif., Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m. Eastern Time (12:25 p.m. Pacific Time).
Nov 14, 2023 03:01 pm ET
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.
Nov 06, 2023 04:00 am ET
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulator
Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study.With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability.Following dialogue with US regulatory authorities, Kodiak plans to conduct one additional pivotal study with a commercial formulation of tarcocimab.New regulatory strategy could support a single Biologics License Application (BLA) for macular edema following retinal vein occlusion (RVO), wet age-related macular degeneration (wAMD) and non-proliferative diabetic retinopathy (
Nov 01, 2023 11:21 pm ET
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL
PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco.
Oct 11, 2023 06:00 am ET
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the p
Aug 02, 2023 05:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kodiak Sciences Inc. – KOD
Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 27, 2023 11:15 am ET
Investigation of Kodiak Sciences Inc. (KOD) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.  On July 24, 2023, Kodiak released top line results from several Phase 3 studies, noting the “GLEAM...
Jul 26, 2023 01:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
NEW YORK, July 26, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jul 24, 2023 06:00 am ET
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab D
PALO ALTO, Calif., July 24, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate.
Jun 05, 2023 10:50 am ET
Thinking about buying stock in Big Lots, DigitalBridge, Retail Opportunity Investments, Kodiak Sciences, or Doximity?
NEW YORK, June 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIG, DBRG, ROIC, KOD, and DOCS.
May 30, 2023 04:15 pm ET
Kodiak Sciences to Present at Upcoming Investor Conferences
PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:
May 15, 2023 04:01 pm ET
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023.
Apr 21, 2023 07:30 am ET
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting
PALO ALTO, Calif., April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that multiple scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, being held from April 23 – 27 in New Orleans, United States.
Apr 03, 2023 07:30 am ET
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases
PALO ALTO, Calif., April 3, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic.
Mar 28, 2023 04:08 pm ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 28, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.
Feb 09, 2023 06:30 am ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 20
PALO ALTO, Calif., Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that a presentation will be made at the upcoming Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting including clinical data from Kodiak's investigational therapy KSI-301 (tarcocimab tedromer) and an update on Kodiak's pipeline of Antibody Biopolymer Conjugate (ABC) development programs.
Jan 04, 2023 06:00 am ET
Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time).
Nov 16, 2022 03:30 pm ET
Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).
Nov 09, 2022 03:01 pm ET
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 9, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended September 30, 2022.
Sep 07, 2022 04:05 pm ET
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
PALO ALTO, Calif., Sept. 7, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time (4:05 p.m. Eastern Time).
Aug 18, 2022 05:47 pm ET
Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)
PALO ALTO, Calif., Aug. 18, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois.
Aug 09, 2022 04:33 pm ET
Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Aug. 9, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2022.
Aug 08, 2022 08:30 am ET
Thinking about buying stock in Bed Bath & Beyond, Kodiak Sciences, Cerevel Therapeutics, Signify Health, or Eargo?
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, KOD, CERE, SGFY, and EAR.
Aug 08, 2022 06:30 am ET
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every monthFirst anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the treatment interval in patients with RVOTarcocimab was well tolerated with a low rate of intraocular inflammation and no new or unexpected safety signalsStudy results will be presented at upcoming ophthalmology scientific meetings in September 2022PALO ALTO, Calif., Aug. 8, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that
Aug 05, 2022 04:30 pm ET
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
PALO ALTO, Calif., Aug. 5, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLOW Phase 3 clinical trial of tarcocimab tedromer (KSI-301), Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with Non-Proliferative Diabetic Retinopathy ("NPDR") without diabetic macular edema ("DME").
May 27, 2022 08:00 am ET
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 9, 2022, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).
May 19, 2022 09:31 am ET
Thinking about buying stock in Chimerix, AT&T, Canada Goose, Kodiak Sciences, or Torm?
NEW YORK, May 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMRX, T, GOOS, KOD, and TRMD.
May 19, 2022 08:00 am ET
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
Purpose-built bioconjugation facility in Lonza's Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseasesThe opening ceremony took place on May 17, 2022 following mechanical completion of the facility in March 2022BASEL, Switzerland and PALO ALTO, Calif., May 19, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza a
May 10, 2022 04:10 pm ET
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 10, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2022.
Apr 29, 2022 05:30 am ET
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
PALO ALTO, Calif., April 29, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations of clinical study data on its investigational therapy KSI-301 will be made at two upcoming vision research conferences: the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colorado, and Retina World Congress 2022 in Fort Lauderdale, Florida.
Mar 01, 2022 03:05 pm ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 1, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2021.
Feb 23, 2022 10:05 am ET
Thinking about buying stock in Palantir Technologies, Kodiak Sciences, Tenneco, Macy's, or Clover Health?
NEW YORK, Feb. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, KOD, TEN, M, and CLOV.
Feb 23, 2022 05:00 am ET
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.
Feb 03, 2022 04:30 am ET
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema
PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3 clinical trials of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with diabetic macular edema ("DME").
Jan 03, 2022 03:05 pm ET
Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time).
Dec 16, 2021 04:30 am ET
Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion
PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with macular edema due to retinal vein occlusion ("RVO").
Nov 09, 2021 03:30 pm ET
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2021.
Nov 08, 2021 03:05 pm ET
Kodiak Sciences to Present at Upcoming Conferences
PALO ALTO, Calif., Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
Sep 01, 2021 05:45 am ET
Kodiak Sciences Announces New Long-Term Performance Incentive Plan
PALO ALTO, Calif., Sept. 1, 2021  /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option awards under a Long-Term Performance Incentive Plan (LTPIP) for named executive officers (NEOs) as well as other eligible Kodiak employees, subject to stockholder approval of the LTPIP at a special meeting expected to be held in October.
Aug 31, 2021 05:02 am ET
Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 8:45 a.m. Pacific Time (11:45 a.m. Eastern Time).
Aug 09, 2021 04:01 pm ET
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Aug. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2021.
May 19, 2021 09:58 am ET
Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors
The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Kodiak Sciences Inc. (“Kodiak”) (NASDAQ: KOD). Kodiak is a clinical stage...
Feb 13, 2021 07:28 am ET
Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal V
PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced promising 1-year durability, efficacy and safety data from the ongoing Phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Feb 02, 2021 06:14 am ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting.
Jan 05, 2021 07:02 am ET
Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual J.P. Morgan Healthcare Conference on Monday January 11, 2021 at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time).
Nov 20, 2020 03:03 pm ET
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 5,972,222 shares of its common stock, which includes 778,985 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $108.00 per share. The aggregate gross proceeds from the offering were app
Nov 17, 2020 08:02 pm ET
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $560.9 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak S
Nov 16, 2020 03:01 pm ET
Kodiak Sciences Announces Proposed Offering of Common Stock
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of shares of its common stock at the public offering price, less underwriting discounts
Nov 16, 2020 05:53 am ET
Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enrollment has been exceeded and recruitment into the study is now clos
Nov 12, 2020 03:12 pm ET
Kodiak Sciences to Present at Upcoming Conferences
PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences:
Nov 11, 2020 10:27 pm ET
Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting
PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.
Nov 09, 2020 04:30 am ET
Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2020.
Jul 16, 2020 04:38 pm ET
Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress
PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors and analysts on Monday, July 27 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Jul 10, 2020 04:00 pm ET
Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and
PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases today announced promising additional safety, efficacy and durability data from the ongoing Phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Jul 07, 2020 08:38 am ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar
PALO ALTO, Calif., July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.
May 28, 2020 08:22 am ET
Kodiak Sciences to Present at Upcoming Conferences
PALO ALTO, Calif., May 28, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences:
May 11, 2020 04:13 pm ET
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference
PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the virtual Bank of America Merrill Lynch Health Care Conference on Wednesday, May 13, 2020 at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time).
May 11, 2020 05:30 am ET
Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2020.
May 08, 2020 04:30 pm ET
Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020
PALO ALTO, Calif., May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tuesday, May 12, 2020 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Apr 02, 2020 04:08 pm ET
Kodiak Sciences Appoints Charles Bancroft to Board of Directors
PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.
Mar 24, 2020 08:51 am ET
"Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use
PALO ALTO, Calif., March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of their trademarks "Kodiak" and "Kodiak Sciences" from the U.S. Patent and Trademark Office for the exclusive use of Kodiak Sciences Inc. and its subsidiaries.
Mar 16, 2020 05:30 am ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.
Nov 12, 2019 04:30 am ET
Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2019.
Nov 08, 2019 06:00 am ET
Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019
PALO ALTO, Calif., Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will report third quarter 2019 results on Tuesday, November 12, 2019.  Following the release of results, Kodiak will host a business highlights webcast at 2:00 p.m. Pacific Time.
Oct 11, 2019 07:58 pm ET
Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occ
PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from its ongoing Phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Oct 11, 2019 06:00 am ET
Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301
PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301. The R&D event, including a live video stream, will be held on Monday, October 14 from 8:00 – 10:30a.m. Pacific Time in San Francisco, CA.
Oct 10, 2019 07:39 pm ET
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak's anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD).
Oct 07, 2019 06:00 am ET
Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff, M.D., Ph.D., will present first-time results at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (October 11 – 12) will feature a presentation of emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-relat
Sep 15, 2019 06:08 am ET
Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting
PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced emerging durability data in patients with wet age-related macular degeneration (AMD) treated in its Phase 1b clinical study of its investigational therapy KSI-301.
Sep 12, 2019 06:00 am ET
Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting
PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London, U.K.
Sep 06, 2019 06:00 am ET
Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference
PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will participate in the Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9 at 4:50 p.m. Eastern Time.
Sep 04, 2019 06:30 pm ET
Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting
PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France.
Aug 14, 2019 05:30 am ET
Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Aug. 14, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019.
Aug 08, 2019 06:00 am ET
Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference
PALO ALTO, Calif., Aug. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 14 at 10:20 a.m. Eastern Time.
Jul 27, 2019 12:47 pm ET
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Ret
PALO ALTO, Calif., July 27, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO). 
Jul 24, 2019 07:00 am ET
Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
PALO ALTO, Calif., July 24, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting being held from July 26 – 30 in Chicago, IL.
May 15, 2019 06:00 am ET
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2019.
May 09, 2019 07:00 am ET
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
PALO ALTO, Calif., May 9, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Wednesday, May 15, at 5:00 p.m. Pacific Time.
Apr 25, 2019 04:05 pm ET
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
PALO ALTO, Calif., April 25, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada.
Mar 28, 2019 06:00 am ET
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
Mar 07, 2019 05:00 am ET
Kodiak Sciences to Present at the Barclays Global Healthcare Conference
PALO ALTO, Calif., March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Barclays Global Healthcare Conference in Miami Beach, FL on Tuesday, March 12 at 1:35 p.m. Eastern Time.
Feb 08, 2019 06:00 am ET
Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
PALO ALTO, Calif., Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
Dec 24, 2018 07:00 am ET
Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes
PALO ALTO, Calif., Dec. 24, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018.
Dec 21, 2018 05:00 am ET
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal
PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported last visit (twelve-week) data from its Phase 1a single ascending dose clinical study of KSI-301, an investigational anti-VEGF antibody biopolymer conjugate, in nine patients with severe diabetic macular edema.
Nov 16, 2018 05:00 am ET
Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Nov. 16, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2018.
Oct 10, 2018 07:00 am ET
Kodiak Sciences Inc. Announces Closing of Initial Public Offering
PALO ALTO, Calif., Oct. 10, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share. The gross proceeds to Kodiak, before deducting underwriting discounts and commissions and offering expenses, were $90 million.  The shares began trading on The Nasdaq Global Market under the ticker symbol "KOD" on October 4, 2018.
Oct 03, 2018 10:59 pm ET
Kodiak Sciences Inc. Announces Pricing of Initial Public Offering
PALO ALTO, Calif., Oct. 3, 2018 /PRNewswire/ -- Kodiak Sciences Inc. ("Kodiak") today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share. In addition, Kodiak has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Kodiak's common stock at the initial public offering price less the underwriting discount. Kodiak's common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol "KOD" on October 4, 2018. The offering is expected to close on

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.